

WHAT IS CLAIMED IS:

1. An isolated or purified peptide comprising Tyrosyl-seryl-valine.
2. An isolated or purified peptide according to claim 1 consisting essentially of the tripeptide Tyrosyl-Seryl-valine.
3. An isolated or purified peptide according to claim 1 consisting of the tripeptide Tyrosyl-Seryl-valine.
4. The peptide of Claim 2 wherein said peptide has an activity selected from the group consisting of modulation of an immune response, stimulation of T lymphocyte transformation, modulation of a cell proliferative disorder, modulation of the growth of a cancer, modulation of the growth of a liver cancer, modulation of the growth of leukemia cells, modulation of the growth of a cervical cancer, modulation of the growth of a lung cancer and the modulation of the growth of a melanoma.
5. A peptide according to any of the Claims 1-4 wherein said peptide is the tripeptide L-Tyrosyl-L-seryl-L-valine.
6. A peptide according to any of the Claims 1-4 wherein said peptide is in a substantially pure form.
7. A pharmaceutical composition comprising a polypeptide comprising the tripeptide Tyrosyl-seryl-valine.
8. A pharmaceutical composition according to Claim 7 comprising the tripeptide L-Tyrosyl-L-seryl-L-valine.
9. A pharmaceutical composition comprising a polypeptide consisting essentially of the tripeptide Tyrosyl-seryl-valine.
10. A pharmaceutical composition according to Claim 9 comprising the tripeptide L-Tyrosyl-L-seryl-L-valine.
11. A pharmaceutical composition comprising a polypeptide consisting of the tripeptide Tyrosyl-seryl-valine.
12. A pharmaceutical composition according to Claim 11 comprising the tripeptide L-Tyrosyl-L-seryl-L-valine.

13. A method of making a pharmaceutical composition comprising providing the tripeptide Tyrosyl-seryl-valine and mixing said tripeptide with a pharmaceutically acceptable carrier.

14. A method of reducing the effects of a human disease comprising administering a pharmaceutically effective dose of the tripeptide Tyrosyl-seryl-valine to a human.

15. The method of Claim 14, wherein said human suffers from a disease selected from the group consisting of a condition whose effects can be reduced by stimulating T lymphocyte transformation and a cell proliferative disorder.

16. The method of Claim 15, wherein said cell proliferative disorder is cancer.

17. The method of Claim 16, wherein said cancer is selected from the group consisting of liver cancer, leukemia, lung cancer, melanoma and cervical cancer.

18. The use of a tripeptide comprising Tyrosyl-seryl-valine as a pharmaceutical compound.

19. The use of a tripeptide consisting essentially of Tyrosyl-seryl-valine as a pharmaceutical compound.

20. The use of a tripeptide consisting of Tyrosyl-seryl-valine as a pharmaceutical compound.

21. The use according to Claim 18, wherein said compound is used for the treatment of a cell proliferative disorder.

22. The use according to Claim 21, wherein said cell proliferative disorder is cancer.

23. The use according to Claim 22, wherein said cancer is selected from the group consisting of liver cancer, leukemia, lung cancer, melanoma and cervical cancer.

24. The use according to Claim 18, wherein said compound is used for the modulation of the immune system.

25. The use of a peptide comprising the tripeptide Tyrosyl-seryl-valine as a nutritional supplement.

26. The use of a peptide consisting essentially of the tripeptide Tyrosyl-seryl-valine as a nutritional supplement.

27. The use of a peptide consisting of the tripeptide Tyrosyl-seryl-valine as a nutritional supplement.

28. A molecule comprising an enhanced derivative of the tripeptide Tyrosyl-seryl-valine, said enhanced derivative comprising an enhancement molecule operably linked to the tripeptide Tyrosyl-seryl-valine, said enhancement molecule enhancing the therapeutic effectiveness of said tripeptide.

29. A peptide consisting essentially of Tyrosyl-seryl-valine.